ALX Oncology Q3 net loss narrows as R&D costs drop

Reuters

Nov 07

ALX Oncology Q3 net loss narrows as R&D costs drop

Overview

ALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&D expenses
Appointed Barbara Klencke, M.D., as interim Chief Medical Officer

Outlook

Company expects cash runway to last into Q1 2027
ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026
Initial safety data for ALX2004 expected in 1H 2026

Result Drivers

R&D EXPENSES - Reduced R&D expenses contributed to a narrower net loss for the quarter

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.41
Q3 Net Income		-$22.14 mln
Q3 Basic EPS		-$0.41
Q3 Income from Operations		-$22.53 mln
Q3 Operating Expenses		$22.53 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $3.00, about 60.7% above its November 6 closing price of $1.18

Press Release: ID:nGNXb38NFx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581883203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581883203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581883203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581883203","market":"fut","top_or_hot":-1,"title":"ALX Oncology Q3 net loss narrows as R&D costs drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ALX Oncology Q3 net loss narrows as R&amp;D costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>ALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&amp;D expenses</p></li><li><p>Appointed Barbara Klencke, M.D., as interim Chief Medical Officer</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash runway to last into Q1 2027</p></li><li><p>ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026</p></li><li><p>Initial safety data for ALX2004 expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Reduced R&amp;D expenses contributed to a narrower net loss for the quarter</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.14 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$22.53 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$22.53 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc is $3.00, about 60.7% above its November 6 closing price of $1.18</p></li></ul><p>Press Release: <span>ID:nGNXb38NFx</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology Q3 net loss narrows as R&D costs drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology Q3 net loss narrows as R&D costs drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ALX Oncology Q3 net loss narrows as R&amp;D costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>ALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&amp;D expenses</p></li><li><p>Appointed Barbara Klencke, M.D., as interim Chief Medical Officer</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash runway to last into Q1 2027</p></li><li><p>ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026</p></li><li><p>Initial safety data for ALX2004 expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Reduced R&amp;D expenses contributed to a narrower net loss for the quarter</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.14 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$22.53 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$22.53 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc is $3.00, about 60.7% above its November 6 closing price of $1.18</p></li></ul><p>Press Release: <span>ID:nGNXb38NFx</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ0KK:1","article_id":"2581883203","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581883203","pubTimestamp":1762521810,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ALX Oncology Q3 net loss narrows as R&D costs dropOverviewALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&D expensesAppointed Barbara Klencke, M.D., as interim Chief Medical Officer","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALXO":"ALX Oncology Holdings"},"translate_title":"随着研发成本下降，ALX Oncology第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":0.9},"content_text":"ALX Oncology Q3 net loss narrows as R&D costs dropOverviewALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&D expensesAppointed Barbara Klencke, M.D., as interim Chief Medical OfficerOutlookCompany expects cash runway to last into Q1 2027ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026Initial safety data for ALX2004 expected in 1H 2026Result DriversR&D EXPENSES - Reduced R&D expenses contributed to a narrower net loss for the quarterKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.41Q3 Net Income-$22.14 mlnQ3 Basic EPS-$0.41Q3 Income from Operations-$22.53 mlnQ3 Operating Expenses$22.53 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $3.00, about 60.7% above its November 6 closing price of $1.18Press Release: ID:nGNXb38NFxFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}